The KDIGO (Kidney Disease: Improving Global Outcomes) 2020 clinical practice guidelines recommend that patient preferences, comorbidities, eGFR, and cost should be considered when approaches of choosing hypoglycemic drugs other than SGLT-2 inhibitors and metformin, if needed GLP-1 RAs are preferred, especially for the T2DM and CKD patients with an eGFR <30 ml/min per 1.73 m2 or those treated with dialysis [158]. This evidence concerns the gene GCG and kidney disorder.